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The pathogenic roles of glomerular deposition of
components of the complement cascade in IgA ne-
phropathy (IgAN) are not completely clarified. To in-
vestigate the pathologic role of complement pathways
in IgAN, two IgAN-prone mouse models were exam-
ined. Grouped ddY (gddY) mice showed significant
high proteinuria, severe glomerular lesions, and ex-
tracellular matrix expansion compared with high se-
rum IgA (HIGA) mice but with similar intensity of
glomerular IgA deposition. Glomerular activation of
the classical, lectin, and alternative pathways was
demonstrated by significantly stronger staining for
complement (C)3, C5b-9, C1q, C4, mannose-binding
lectin (MBL)-A/C, MBL-associated serine protease-2,
and factor B and properdin in gddY mice than in
HIGA mice. Similarly, the serum levels of IgA-IgG2a/
IgM and IgA–MBL-A/C immune complexes and poly-
meric IgA were significantly higher in gddYmice than
in HIGA mice. Moreover, the serum levels of aber-
rantly glycosylated IgA characterized by the binding
of Sambucus nigra bark lectin and Ricinus communis
agglutinin I were significantly higher in gddY mice
than in HIGAmice. This aberrancy in glycosylationwas
confirmed by monosaccharide compositional analysis
of purified IgA using gas-liquid chromatography. This
study is the first to demonstrate that aberrantly glyco-
sylated IgA may influence the formation of macromo-
lecular IgA including IgA-IgG immune complexes and
subsequent complement activation, leading to full pro-
gression of IgAN. (Am J Pathol 2012, 181:1338–1347; http://
dx.doi.org/10.1016/j.ajpath.2012.06.038)
1338IgA nephropathy (IgAN) was first reported in 1968 by
Berger and Hinglais1 and is a common form of progres-
sive primary glomerulonephritis. The major histologic
characteristics of IgAN are mesangial cell proliferation
and matrix expansion with granular deposition of IgA,
predominantly polymeric IgA1 (pIgA1),2 and comple-
ment (C)3 in the glomerular mesangial areas. This depo-
sition in glomeruli may provide insights into IgAN patho-
genesis. In IgAN, IgA1 has aberrant glycosylation of
O-glycans in the hinge region3,4 and is predominantly in
the polymeric form (pIgA).2,5–7 However, the pathologic
interaction between the complement cascade and pIgA
has not been completely clarified in IgAN.
Three different pathways of complement activation have
been described. The classical pathway is triggered by ac-
tivation of the C1 complex (composed of one molecule of
C1q, two molecules of C1r, and two molecules of C1s, thus
forming C1qr2s2).This activation occurs when C1q binds to
IgM- or IgG-antigen complexes or when C1q binds directly
to the surface of a pathogen. The lectin pathway is homol-
ogous to the classical pathway but contains opsonin, man-
nose-binding lectin (MBL), and ficolins instead of C1q. This
pathway is activated by binding of MBL to mannose resi-
dues on the pathogen surface, thereby leading to activation
of MBL-associated serine proteases (MASP-1 and MASP-
2). These proteases split C4 into C4a and C4b and C2 into
C2a and C2b. Similar to that in the classical pathway, C4b
and C2a then bind together to form C3 convertase. The
alternative pathway is triggered by spontaneous C3 hydro-
lysis [C3(H2O)] directly due to the breakdown of the thioes-
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plasma protein factor B [C3(H2O)Bb, C3 convertase]. This
convertase cleaves C3 proteins into C3a and C3b, which
are then capable of covalently binding to a pathogenic
membrane surface. Properdin is a component of the alter-
native pathway. It forms complexes with C3b to stabilize the
alternative C3 convertase that further cleaves more C3. In
all three pathways, C3 convertase cleaves and activates
component C3 by forming C3a and C3b. It also cleaves C5
into C5a and C5b. C5b initiates the membrane attack path-
way by forming a membrane attack complex with other
recruited complement components (C6, C7, C7, C8, and
multiple C9 molecules). Membrane attack complex is the
cytolytic end product of the complement cascade. It forms
a transmembrane channel that causes osmotic lysis of the
target cell.
We used IgAN animal models to investigate IgAN patho-
genesis. The ddY mouse is an animal model of spontane-
ous IgAN. Glomerular lesions in this mouse include mesan-
gial proliferation and extracellular matrix expansion with
paramesangial IgA deposition that closely resemble those
found in human IgAN.8 In pooled serum and glomerular
elutes of 16-, 40-, and 60-week-old ddY mice, the ratio of
dimeric IgA and pIgA in total IgA increases markedly with
age.9 However, the IgAN incidence in commercially avail-
able ddY mice is highly variable.10 The high serum IgA
(HIGA) mouse is one of the IgAN models derived from the
ddY mouse.11 This mouse is an inbred strain derived from
ddY mice by selective mating of animals with high serum
IgA levels. No renal abnormalities manifest in the HIGA
mouse until approximately 10 weeks of age, with serum IgA
levels increasing dramatically thereafter and becoming
elevated by 25 weeks of age. Although this mouse shows
high serum IgA levels, the increase is not associated with
the severity of glomerular injury and the incidence of IgAN.
We have evaluated commercially available ddY mice using
serial renal biopsies obtained at 20, 40, and 60 weeks of
age. These mice were divided into three groups: early-
onset (approximately 20 weeks), late-onset (approximately
40 weeks), and quiescent (even at 60 weeks) mice.12 In
ddYmice with disease onset, the levels of serum IgA-IgG2a
immune complex (IC) correlated strongly with the severity of
glomerular lesions,13 although no significant correlation was
observed between serum IgA levels and the incidence of
glomerular injury among the groups. We bred early-onset
mice in a specific pathogen–free room and established a
mouse IgAN model with an almost 100% incidence of the
disorder.14 This mouse strain was called grouped ddY
(gddY). Although the HIGA and gddY models are derived
from ddY mice, their ratios of disease onset, phenotype,
and disease severity are very different. In this study, we
examined these differences from the aspect of complement
activation.
Materials and Methods
Mice
Eleven female gddY mice were maintained at the animal
facility of Juntendo University, Tokyo, Japan. The micewere fed regular chow (Oriental Yeast Co. Ltd., Tokyo,
Japan) and water ad libitum and were housed in a spe-
cific pathogen–free room. Age-matched female HIGA
and BALB/c mice were maintained in an identical man-
ner. The experimental protocol was approved by the Eth-
ics Review Committee for Animal Experimentation of Jun-
tendo University Faculty of Medicine.
Measurement of Urinary Albumin and Creatinine
Levels
Urinary albumin levels were measured using an enzyme-
linked immunosorbent assay kit (Exocell Inc., Philadel-
phia, PA). Using a commercial kit (Exocell Inc.), urinary
creatinine levels were measured based on Jaffe’s reac-
tion with alkaline picrate. Urinary albumin was normalized
to urinary creatinine.
Histologic Analysis
Kidneys were obtained after perfusion with normal saline.
Renal tissue specimens for microscopic evaluation were
fixed in 15% formaldehyde, embedded in paraffin, cut
into 3-m-thick sections, and then stained with H&E and
PAS. The mesangial area in the renal specimen of each
mouse was determined by calculating the mean nucleus-
free, PAS-positive area in 20 glomeruli located in the
glomerular hilus, as described previously.15
Renal specimens for immunofluorescence (IF) were
mounted in OCT compound (Sakura Finetek Japan Co.
Ltd., Tokyo, Japan) and stored at 80°C. The specimens
were then cut into 3-m-thick sections, fixed with acetone
at 20°C for 4 minutes, and stained (IF staining) for IgA,
IgG2a, C3, C4, C1q, C5b-9, MBL-A, MBL-C, MASP-2,
and factor B and properdin. In brief, the sections were
washed with PBS, blocked with a blocking agent (DS
Pharma Biomedical Co. Ltd., Osaka, Japan) at room tem-
perature for 30 minutes, and then incubated at room
temperature for 60 minutes with the following primary
antibodies: goat anti-IgA, goat anti-IgG2a (Bethyl Labo-
ratories Inc., Montgomery, TX), rat anti-C3, rat anti-C4, rat
anti-C1q, rat anti-MBL-A, rat anti-MBL-C (Hycult Biotech,
Uden, The Netherlands), anti-MASP-2, anti-factor B and
anti-properdin (Santa Cruz Biotechnology, Santa Cruz,
CA), and anti-C5b-9 (Abcam Inc., Cambridge, MA). After
three washes with PBS, the samples were incubated for
30 minutes with secondary antibodies compatible with
the primary antibody to some degree, washed, and then
mounted in mounting medium (Dako, Tokyo, Japan). Im-
ages were taken using a confocal laser microscope
(Olympus Corp., Tokyo, Japan) with the same detector
sensitivity for the same target antigen. The fluorescence-
positive area was determined using ImageJ software
(National Institutes of Health, Bethesda, MD) as de-
scribed previously.15 For double IF staining (IgA-IgG2a,
IgA–MBL-A, IgA–MBL-C, and IgA-C1q), the primary and
secondary antibodies were added to the incubation mix-
ture. Rabbit anti-mouse IgG2a was detected using Cy5-
conjugated donkey anti-rabbit IgG antibody. The other
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ondary antibodies that were used for single IF staining.
An enzyme-labeled antibody method was used to as-
sess type IV collagen expression in the paraffin-embed-
ded sections. After deparaffinization and rehydration, the
renal sections were washed twice for 5 minutes with PBS.
The sections were treated with 0.3% H2O2 for 30 minutes
to block endogenous peroxide activity. They were then
incubated at room temperature for 60 minutes with anti-
type IV collagen antibody (AbD Serotec MorphoSys, Ox-
ford, UK). After reaction with the primary antibody, the
sections were reacted with horseradish peroxidase–con-
jugated goat anti-rabbit antibody (Nichirei Biosciences,
Tokyo, Japan) and then visualized by treatment with di-
aminobenzidine (Dako). Quantitative analysis of type IV
collagen expression in the glomerular areas was per-
formed using minor modifications of a previously de-
scribed method.16 In brief, 20 random glomerular cross
sections were chosen from each tissue section and ex-
amined. The examined areas were outlined, the positive
staining patterns were identified, and the percentage of
positive staining area in each glomerular cross section
was then measured. Three nephrologists and patholo-
gists quantified them in a blinded manner. To check the
specificity of antibodies used, we examined kidneys of
NOD SCID mice and MBL knockout mice as negative
controls (data not shown).
Isolation of Glomeruli and Quantification of Type
IV Collagen mRNA Expression
Glomeruli were isolated by a sieving technique. Total
RNA was purified from the isolated glomeruli using an
RNA extraction kit (Qiagen, Tokyo, Japan) according to
the manufacturer’s instructions. Aliquots (500 ng) of total
glomerular RNA were reverse transcribed (Life Technol-
ogies, Tokyo, Japan) and were analyzed using a real-
time PCR system (Life Technologies) and Power SYBR
green PCR master mix (Life Technologies). The primer
sequence for type IV collagen has been published pre-
viously.17 Mouse glyceraldehyde-3-phosphate dehydro-
genase was chosen as the housekeeping gene. All real-
time PCR measurements were performed in triplicate and
included no template controls. The glomerular transcript
abundance of type IV collagen was calculated by the
2CT method.18
Measurement of Serum IgA and Aberrantly
Glycosylated IgA Levels
Serum IgA levels were measured using a sandwich en-
zyme-linked immunosorbent assay (ELISA) kit (Bethyl
Laboratories Inc.). Aberrantly glycosylated bound serum
IgA levels were measured using biotinylated Sambucus
nigra bark lectin (SNA; Vector Laboratories, Burlingame,
CA) and Ricinus communis agglutinin I (RCA-I; Vector
Laboratories).19 Microtiter plates coated with goat anti-
mouse IgA used for quantification of serum IgA were
incubated with these samples, and biotinylated SNA or
RCA-I was then added. Horseradish peroxidase–avidin D(Vector Laboratories) was applied, and color developed
after 15 minutes of exposure to 3,3=,5,5=-tetramethylben-
zidine (Becton Dickinson, Tokyo, Japan). The color de-
velopment reaction was stopped by adding 2 N of
H2SO4, and absorbance at 450 nm was read using a
microplate reader (Nihon Molecular Devices, Tokyo, Ja-
pan). A standard curve was produced for each of the two
lectins using serial dilutions of the reference serum
(Bethyl Laboratories Inc.). The quantity of lectin bound to
1 g of IgA was defined as 1 U. All the samples were
reduced by 9% 2-mercaptoethanol (Wako Pure Chemical
Industries Ltd., Tokyo, Japan) to avoid the influence of
lectin binding by other constituent molecules in IgA-IC.
Western blot analysis using serum samples under the
reducing condition confirmed that the IgA-IgG IC was
resolved (data not shown).
Monosaccharide Compositional Analysis of IgA
by Gas-Liquid Chromatography
IgA was purified from sera of gddY and HIGA mice, and
the purity of the preparations was assessed by SDS-
PAGE. Trichloroacetic acid-precipitated 10-g protein for
each IgA sample was analyzed by gas-liquid chromatog-
raphy with sorbitol as the internal standard. The analyses
were performed using a gas chromatograph (model
5890; Hewlett-Packard, Sacramento, CA) equipped with
a 25-m fused silica (0.22-mm inner diameter) OV-1701
wall-coated open tubular column (Chrompack Inc.,
Bridgewater, NJ) and an electron capture detector. Stan-
dard sugars were used for quantification. The results are
expressed relative to the internal standard and specific
sugar standard, using the area under the peak in
chromatograms.20,21
Measurement of Serum IC Levels
Serum IC (IgA-IgG2a, IgA–MBL-A, and IgA–MBL-C) lev-
els were measured by sandwich ELISA using a modifi-
cation of a method described previously.13 In brief, mi-
crotiter plates (Nalge Nunc International, Tokyo, Japan)
were coated with anti-mouse IgA antibody. After incuba-
tion, the microtiter plates were washed with PBS contain-
ing 0.05% Tween 20 and then were blocked at room
temperature for 60 minutes with 250 L per well of block-
ing solution (1% blocking agent with PBS containing
0.05% Tween 20). The plates were then stored at 4°C
until use. The microtiter plates coated with antibody were
loaded in duplicate with diluted serum and were incu-
bated at room temperature for 60 minutes. In the assay
for the measurement of IgA-IgG2a complexes, the sam-
ple and antibody were diluted with blocking solution. For
other complex assays, the samples were diluted with PBS
containing 1 mmol/L CaCl2 and the antibody was diluted
with blocking solution containing 1 mmol/L CaCl2. After
washing with PBS containing 0.05% Tween 20, 90 L per
well of anti-IgG2a–horseradish peroxidase was used in
the IgA-IgG2a complex assays. After incubation at room
temperature for 60 minutes, 90 L of 3,3=,5,5=-tetrameth-
ylbenzidine was added to each well. In the other assays,
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and was incubated at room temperature for 60 minutes.
After the plates were washed, biotinylated donkey anti-rat
IgG was applied. After 60-minute incubation at room tem-
perature, the microplates were washed five times with
PBS containing 0.05% Tween 20, and horseradish per-
oxidase–avidin D was applied. After 60-minute incuba-
tion and further washing, the color was developed by
3,3=,5,5=-tetramethylbenzidine using the same method
described for IgA-IgG2a IC. In all the assays, the color
development reaction was stopped by adding 90 L of 2
N H2SO4 to each well, and absorbance at 450 nm was
read using the microplate reader. For comparison, each
absorbance was adjusted for the serum IgA level.
Determination of the Molecular Weight of IgA
The molecular weight of IgA was determined by Western
blot analysis using a modification of a method described
previously.22 The serum was resolved by 5% to 20%
gradient SDS-PAGE and was transferred onto polyvi-
nylidene difluoride membranes (Nihon Millipore KK, To-
kyo, Japan). The membranes were blocked with 4%
blocking solution and then were incubated with diluted
goat anti-mouse IgA at room temperature for 60 minutes.
After washing in PBS, the sections were incubated with
the secondary antibody that corresponded to the primary
antibody used. IgA was detected by chemiluminescence
using ECL (GE Healthcare, Tokyo, Japan) and radiogra-
phy (Konica Minolta Healthcare, Tokyo, Japan). The sam-
ples were analyzed under nonreducing conditions.
Statistical Analysis
The data are expressed as mean  SD. The statistical
significance of the experimental observations was deter-
mined by analysis of variance, with the level of signifi-
cance set at P 0.05. Descriptive statistical analysis was
performed using statistical software (IBM Japan, Tokyo,
Japan).
Results
Glomerular Injury in gddY Mice Is More Severe
than in HIGA Mice despite the Same Degree of
IgA Deposition
The severity of glomerular injury was examined in both
IgAN-prone strains of mice. The urinary albumin level in
gddY mice at 11 weeks of age was considerably higher
than that in age-matched HIGA mice (Figure 1A). Mes-
angial matrix expansion in gddY mice was also more
severe than that in HIGA mice (Figure 1, B and C). Fur-
thermore, expression of type IV collagen mRNA and pro-
tein in gddY mice was higher than that in HIGA mice
(Figure 1, D–F). Although the degree of glomerular injury
was very different in the two strains of mice, glomerular
IgA deposition was identical in both IgAN-prone mouse
strains (Figure 1, G and H).Glomerular Complements Are More Activated
by the Three Pathways in gddY Mice than in
HIGA Mice
The degree of activation of complement pathways was
investigated in murine IgAN. IF staining showed that
glomerular deposition of C3 and C5b-9 was more
abundant in gddY mice than in HIGA mice (Figure 2A).
This finding indicated greater complement activation in
gddY mice.
To identify which complement pathways were in-
volved, the key components of the three pathways were
measured. The positive areas of glomerular C1q and C4
staining in gddY mice were significantly higher than those
in HIGA mice (Figure 2C), indicating that the classical
pathway in gddY mice was considerably more activated
than that in HIGA mice. Next, the components of the
lectin pathway, such as MBL-A/C and MASP-2, were
analyzed in the glomeruli of both IgAN-prone strains of
mice (Figure 2B). The amount of MBL-A/C deposition in
gddY mice was significantly higher than that in HIGA
mice. Similarly, the positive area of MASP-2 staining in
gddY mice was also significantly higher than that in HIGA
mice. These findings indicated that activation of the lectin
pathway in glomeruli of gddY mice was higher than that in
glomeruli of HIGA mice. Furthermore, the positive area of
glomerular factor B and properdin staining in gddY mice
was significantly higher than that in HIGA mice (Figure
2D). This finding indicated that the alternative pathway in
gddY mice was also markedly more activated than that in
HIGA mice.
Levels of IgA-IC in Sera and Glomeruli Are
Markedly Increased in gddY Mice Compared
with Levels in HIGA Mice
To assess why the classical pathway was more acti-
vated in gddY mice, the characteristics of glomerular
ICs and their serum levels were investigated. Although
serum IgA levels in HIGA mice were significantly higher
than those in gddY mice (Figure 3A), the serum level of
IgA-IgG2a IC per unit of IgA in gddY mice was signif-
icantly higher than that in HIGA mice (Figure 3B). Dou-
ble IF staining showed that C1q was co-deposited with
IgG2a and IgM (Figure 3, C and D). However, the
positive area of glomerular IgG2a and IgM staining in
gddY mice was significantly higher than that in HIGA
mice (Figure 3, C and D).
Amounts of MBL Associated with Serum IC and
Co-Deposited with IgA in Glomeruli Are
Considerably Higher in gddY Mice than in HIGA
Mice
To assess the underlying mechanism that caused greater
activation of the lectin pathway in gddY mice, MBL bind-
ing to IgA-IC was investigated (Figure 4). MBL-A and
MBL-C were co-localized with IgA (Figure 4, A and B).
Although serum IgA levels were significantly higher in
ted in e
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bound to IgA-IC in gddY mice were significantly in-
creased compared with those in HIGA mice (Figure 4,
C and D).
gddY and HIGA Mice Have pIgA, although gddY
Mice Had Higher Amounts of Aberrantly
Glycosylated IgA than HIGA Mice
The molecular forms of serum IgA were analyzed in two
IgAN-prone strains of mice (Figure 5). The amount of
high-molecular-weight IgA in HIGA mice was higher than
that in gddY mice (Figure 5A), similar to the situation
Figure 1. Glomerular injury in gddY mice is more severe than that in H
Glomerular lesions and PAS-positive areas in glomeruli of gddY mice we
mice. D–F: Glomerular type IV collagen (Col IV) expression in each IgAN
in gddY mice than in HIGA mice. G and H: Glomerular IgA deposition
rular IgA deposition in gddY and HIGA mice. Eleven mice were evalua
***P  0.001.observed for serum IgA levels. After compensation byserum IgA levels, the amount of high-molecular-weight
IgA in gddY mice was not different from that in HIGA mice
(Figure 5A).
Next, the lectin-binding assays were used19 to access
the glycoform of IgA in both IgAN-prone strains of mice.
This assay was designed using biotinylated SNA and RCA-I
that recognize terminal sialic acid (particularly Neu5Aca2-
6Gal) and galactose residues, respectively. Serum IgA from
gddYmice showed a significantly lower affinity to lectin SNA
and RCA-I than that from HIGA mice (Figure 5B). These
findings suggest that the content of terminal sialic acid
(amount of binding lectin SNA) and terminal galactose
(amount of binding RCA-I) on IgA in gddY mice was signif-
e. A: Proteinuria at 11 weeks [albumin creatinine ratio (ACR)]. B and C:
icantly more severe than those in glomeruli of HIGA and control BALB/c
mouse. Expression of Col IV mRNA and protein was significantly higher
IgAN-prone mouse. No significant difference was observed in glome-
ach group. The bars represent mean  SD. *P  0.05, **P  0.01, andIGA mic
re signif
-prone
in eachicantly less than that on IgA in HIGA mice.
din stai
0.001, a
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gddY Mice Was Confirmed by Monosaccharide
Compositional Analysis
Monosaccharide compositional analysis of purified IgA
from gddY and HIGA mice was determined by gas-liquid
Figure 2. Glomerular complement cascades were strongly activated in gddY
in gddY mice was stronger than that in HIGA mice. B: Lectin pathway: the po
mice than that in HIGA mice. C: Classical pathway: the positive area of glo
D: Alternative pathway: the positive area of glomerular factor B and proper
evaluated in each group. The bars represent mean  SD. *P  0.01, **P 
Figure 3. Levels of IgA-IgG2a IC in sera and glomerular deposition were
markedly increased in gddY mice compared with HIGA mice. A: The serum
IgA level was significantly higher in HIGA mice than in gddY and control
mice. B: However, the serum level of IgA-IgG2a IC was significantly higher
in gddY mice than in HIGA and control mice. IgG2a (C) and IgM (D) were
co-localized with C1q in the glomeruli of both IgAN-prone strains of mice.
The intensity of IgG2a, IgM, and C1q staining was significantly higher in
gddY mice than in HIGA mice. Eleven mice were evaluated in each group.
The bars represent mean  SD. *P  0.01, **P  0.001, and ***P  0.0001chromatography. Sugar composition was consistent with
the result of a lectin ELISA using SNA and RCA-I. Spe-
cifically, monosaccharide composition revealed that IgA
purified from sera of gddY mice had a lower content of
A: Common pathway: the positive area of glomerular C3 and C5b-9 staining
rea of glomerular MBL-A, MBL-C, and MASP-2 staining was stronger in gddY
r C1q and C4 staining in gddY mice was stronger than that in HIGA mice.
ning in gddY mice was stronger than that in HIGA mice. Eleven mice were
nd ***P  0.0001.
Figure 4. gddY mice showed greater activation of the lectin pathway. Serum
levels of IgA–MBL-A IC (A) and IgA–MBL-C IC (B) were significantly higher in
gddY mice than in HIGA mice. MBL-A (C) and MBL-C (D) were co-localizedmice.
sitive a
merulawith IgA in both IgAN-prone strains of mice. Elevenmice were evaluated in each
group. The bars represent mean  SD. *P  0.01, **P  0.001.
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from sera of HIGA mice (Table 1).
Discussion
The degree of glomerular injury was more severe in gddY
mice than in HIGA mice. gddY mice showed marked
glomerular deposition of C5b-9 and C3 compared with
HIGA mice, suggesting that in situ activation of the com-
plement cascade was greater in gddY mice. This finding
is compatible with the report that C5b-9 staining is more
intense in human IgAN cases with advanced glomerular
lesions than in those with minimal glomerular lesions.23
An in vitro study showed that sublytic C5b-9, which can
induce injury in the mesangial cells, can induce complete
DNA synthesis in these cells.24 Disease progression
may, therefore, be attributed to the end products of the
complement cascade, namely, C5b-9.
Using histologic analyses, this study showed activation
of the three complement pathways (classical, lectin, and
alternative) in glomeruli. Although C1q is not usually de-
tected in glomeruli in human IgAN, there is evidence that
cases with C1q deposition tend to become more se-
vere.23,25–27 Furthermore, co-deposition of IgA, IgG, and
IgM in glomeruli, the so-called full house pattern, is ob-
served in association with C1q.28 In human IgAN, ICs
containing pIgA1 have a high molecular mass of approx-
imately 800 to 900 kDa.29 These ICs can pass through
Figure 5. gddY mice had higher amounts of circulatory aberrantly glycosy-
lated IgA than HIGA mice. A: Levels of serum IgA were increased in HIGA
mice (left panel). However, after adjustment for serum IgA levels, high-
molecular-weight IgA was more abundant in gddY mice (right panel). The
loaded samples under reducing conditions were developed with anti-IgA
antibody (lower panels). B: Serum IgA in gddY mice showed significantly
lower binding to lectin SNA than that in HIGA and BALB/c mice and signif-
icantly lower binding to RCA-I than that in BALB/c mice. Eleven mice were
evaluated in each group. The bars represent mean  SD. *P  0.01.the larger fenestrate of endothelial cells in the glomerularcapillaries (500–1000 Å) and get deposited in the mes-
angium.30 The present study showed that gddY mice had
higher serum levels of IgA-IgG2a ICs13 than HIGA
mice. In addition, glomerular depositions of IgG2a and
IgM were more abundant in gddY mice than in HIGA
mice. Because the classical pathway is activated
mainly by IgG and IgM in ICs,31 elevation of serum and
glomerular levels of IgA-IgG2a or IgA-IgM ICs in gddY
mice may accelerate activation of the classical path-
way in glomeruli.
Previous in vitro studies have shown that aggregated
pIgA, but not monomeric IgA, can bind to MBL in a
dose-dependent manner.32 This earlier report also dem-
onstrated that pIgA activated the complement system via
the lectin pathway to a greater degree than dimeric IgA,
whereas no significant activation could be detected with
monomeric IgA. Approximately 25% of patients with IgAN
show glomerular deposition of MBL, L-ficolin, MASP, and
C4d33 as proof of activation of the lectin pathway. These
patients with IgAN are generally younger than those with-
out such activation. In addition, the duration from disease
onset to biopsy in such patients is shorter than that in
patients without activation.34 We showed that co-deposi-
tion of MBL with IgA in glomeruli of IgAN models or with
the lectin pathway in gddY mice was similar and was
more activated than in HIGA mice. In addition to MBL
deposition, we detected elevation in the serum levels of
IgA–MBL-A/C IC in both IgAN models. However, the lev-
els of IgA-MBL ICs in gddY mice were higher than those
in HIGA mice, suggesting that serum IC consisting of
aberrantly glycosylated IgA binds to MBL, thereby acti-
vating the lectin pathway in glomeruli.
The present study also demonstrated increased inten-
sity of properdin and factor B staining in gddY mice
compared with that in HIGA mice. In human IgAN, pro-
perdin and factor B are observed in glomeruli.23,35 In
general, in situ deposition of properdin and factor B char-
acterizes activation of the alternative pathway. C3b binds
covalently to pathogenic membrane surfaces. The
amount of C3b binding to the IgA molecule was in-
creased by removing sialic acid and N-linked glycan
chains from normal serum IgA1 and IgA2.36 There is
evidence that sialylation and galactosylation of O-gly-
cans in the hinge region of human serum IgA1 are de-
creased to a greater degree in patients with IgAN than in
Table 1. Monosaccharide Composition of Murine IgA
Determined by Gas-Liquid Chromatography
Sugar HIGA mice gddY mice
Mannose 0.485 0.204
GlcNAc 0.274 0.141
GalNAc ND ND
Galactose 0.302 0.148
SA 0.257 0.135
IS 1.000 1.000
Data are expressed as the average of two experiments relative to
standard sugars and normalized to the IS, based on the area under the
peak in the chromatograms. Ten micrograms of IgA was used per
sample.GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine; IS,
internal standard; ND, not detected; SA, sialic acid.
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controls.37 On the basis of these studies, we suggest that
aberrantly glycosylated IgA complexed with C3b and
factor B are co-deposited in glomeruli. Properdin mRNA
is strongly expressed in human glomeruli,38 indicating
that C3bBb is stabilized by binding to properdin in situ
and, thus, leads to activation of the alternative pathway.
In addition to the ability of stabilization, properdin can
direct complement activation more selectively by recog-
nizing and binding to specific target surfaces referred to
as the properdin-directed pathway.39,40 The other mech-
anism of activation of the complement cascade in this
study is the ability of properdin binding to apoptotic
cells38 and necrotic cells,41 initiating in situ activation of
complement cascade. Although this mechanism in hu-
man IgAN is not really investigated, 18% of patients with
lupus nephritis with properdin depositions on glomeruli
without factor B assumed that properdin deposition might
lead to properdin-directed pathway activation with dis-
ease progression.42
It is well-known that pIg or high-molecular-weight ICs
have more potency for complement activation in all the
pathways than do oligomeric Ig or low-molecular-weight
ICs.7,43–46 One of the most important findings of this
study is that the phlogogenic potency, via complement
pathways leading to full progression of IgAN, is more
dependent on the molecular form of IgA than on the
amounts of glomerular IgA deposition. Therefore, one
can speculate that the greater complement activation in
gddY mice may essentially be due to a higher molecular
form of IgA, including IgA-IgG IC, rather than to aberrant
glycosylation of IgA itself. Indeed, to our knowledge, no
study has found any direct evidence linking the aber-
rantly glycosylated IgA to complement activation or even
the glomerular damage in human IgAN.
However, the aberrant glycosylation of IgA should im-
portantly contribute to the high molecular formation. In
human IgAN, many studies have reported serum eleva-
tion of pIgA and high-molecular-weight IgA1 levels due to
self-aggregation and formation of ICs composed of ab-
errantly O-glycosylated IgA and anti-glycan IgG.47–50
Moreover, extracted IgA1 from mesangial deposits are
also aberrantly glycosylated.3,4
Although mice do not have IgA molecules with struc-
tural analogy to human IgA1, a recent study has demon-
strated the presence of O-linked glycans in the hinge
region of an IgA rheumatoid factor, and its potential to
induce IgAN-like glomerular lesions was associated with
increased levels of O-glycosylation.51 In addition, gddY
and HIGA mice carry a potential O-glycosylation accep-
tor site in the hinge region of IgA,14 suggesting the pos-
sibility that only a minor fraction of IgA is O-glycosylated
and exhibits a pathogenic potency in gddY mice, as
speculated in human IgAN. On the other hand, deficiency
of 1,4-galactosylation and sialylation of N-glycan by
gene targeting of 1,4-galactosyltransferese-I induces
murine IgAN with serum elevation of polymeric forms of
IgA and glomerular IgG co-depositions.52 In the present
study, we found that gddY mice have increased levels of
high-molecular-weight IgA and IgA-IC. Present lectin
binding assays suggest that it may be due to the differ-ences of oligosaccharide contents in IgA compared with
HIGA mice. To further address this question, more exten-
sive biochemical analysis of sugar contents was con-
ducted by gas-liquid chromatography. The analysis of
sugar contents revealed that purified IgA from gddY mice
had lower contents of oligosaccharides compared with
IgA from HIGA mice (Table 1). This finding, thus, indi-
cates that aberrantly glycosylated IgA, whether alteration
of the glycosylation site is O-glycan or N-glycan, can
promote the development of macromolecular formation of
IgA including IgG autoantibodies against sugar moiety
on IgA in gddY mice, as in the case of human IgAN.48
Conclusion
The present study demonstrated that the classical, lectin,
and alternative pathways of the complement cascade are
activated in glomeruli in murine IgAN. More severe glo-
merular injury associated with greater activation of these
pathways is observed in gddY mice. These differences
between gddY and HIGA mice may be because of the
degree of serum macromolecular IgA including IgA-IC
with IgG/IgM or MBL-A/C. We further hypothesized that
aberrantly glycosylated IgA importantly contributes to the
formation of high-molecular-weight IgA and IgA-IC and
subsequent complement activation, leading to full pro-
gression of IgAN (Figure 6).
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